Overview

A Long Term Safety Study With Atrasentan

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Abbott
Treatments:
Atrasentan